Email:

Contact Us

CSPC Pharmaceutical Group Co., Ltd.

News

News

Home > Media > News > Antibody-Drug Conjugate Cpo204 Obtains Clinical Trial Approval In The U.S.

Antibody-Drug Conjugate Cpo204 Obtains Clinical Trial Approval In The U.S.

November 29, 2022

微信截图_20221207104516.png

Previous: CSPC Selected as Mercer China Healthiest Workplace

Next: "SYSH1901"Obtains Clinical Trial Approval for Covid-19

Phone:

+86 311 8703 7015

Email:

Legal terms Privacy protection

Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |